Ratings Vir Biotechnology, Inc.

Equities

VIR

US92764N1028

Delayed Nasdaq Other stock markets 20:49:09 02/05/2024 BST			5-day change	1st Jan Change
9.11 ^USD	+4.23%		+19.20%	-9.59%

04-26	Cytokinetics Appoints Sung Lee as CFO	MT
04-18	Vir Biotechnology, Inc. Announces Stepping Down of Sung Lee as Chief Financial Officer, Effective May 3, 2024	CI

Strengths

Thanks to a sound financial situation, the firm has significant leeway for investment.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
The company's "enterprise value to sales" ratio is among the highest in the world.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
Over the past twelve months, analysts' opinions have been revised negatively.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
VIR BIOTECHNOLOGY, INC.	-9.59%	1.19B	C+
MODERNA, INC.	+26.50%	42.68B	B-
IQVIA HOLDINGS INC.	-4.13%	42.4B	B
LONZA GROUP AG	+45.32%	40.04B	A
CELLTRION, INC.	-6.20%	28.31B	C
ICON PUBLIC LIMITED COMPANY	+6.64%	24.94B	B-
ALNYLAM PHARMACEUTICALS, INC.	-21.53%	18.96B	B
MEDPACE HOLDINGS, INC.	+27.56%	12.3B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.94%	11.95B	C+
BIO-TECHNE CORPORATION	-1.76%	11.55B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes